Organs-On-Chips Market Size, Share & Industry Analysis by Offering (Products {Devices and Consumables & Accessories} and Services), By Organ Model (Liver-on-a-Chip, Lung-on-a-Chip, Intestine-on-a-Chip, Kidney-on-a-Chip, and Others), By Application (Drug Discovery & Development, Toxicology Research, Disease Modeling, and Others), By End-user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Others), and Regional Forecast, 2025-2032

The global organs-on-chips market size was valued at USD 154.1 million in 2024. The market is projected to grow from USD 210.4 million in 2025 to USD 1,322.0 million by 2032, exhibiting a CAGR of 30.0% during the forecast period. North America dominated the Organs On Chips Market with a market share of 223.98% in 2024.

Organ-on-a-chip, a microengineered device with living cells in microfluidic channels, offers a stimulation to the physiological functioning of organs in the human body. These chips are useful in research and testing as they mimic fluid flow, tissue interfaces, and mechanical forces for replicating the behavior of real organs. Furthermore, they can model human responses without the deployment of animal testing. The chip adoption is surging with the mounting demand for more accurate, cost-effective, ethical alternatives to animal testing in the areas of toxicity studies and drug development. This is expected to fuel market growth.

Furthermore, the market is dominated by Emulate, MIMETAS, InSphero, and CN Bio. These players have a significant focus on increasing product reach to key countries. This is expected to help them capture a major portion of the market.

MARKET DYNAMICS

MARKET DRIVERS

Increasing Demand for Predictive Preclinical Models to Propel the Market Growth

Biotech and pharma companies have been seen adopting organ-on-chip systems at a rising rate owing to the provision of human-relevant and highly predictive data compared to traditionally used animal models or 2D cell cultures. These microfluidic platforms improve the predictability of toxicity and drug efficacy analyses as they streamline the research process by replicating the physiology of real organs. The technology enables the identification of ineffective and unsafe compounds at an early stage and even though the R&D costs in general and clinical failure rates are high, it helps save resources and time during the drug development process. This inclination toward reliability and precision in the area of preclinical testing is anticipated to propel the global organs-on-chips market growth over the forthcoming years.

• For instance, Emulate’s Liver-Chip S1 has been accepted into the FDA’s ISTAND pilot program, marking a major milestone toward regulatory qualification of Organ-Chip technologies for drug safety testing. The tool demonstrated up to 87% sensitivity and 100% specificity in predicting drug-induced liver injury, paving the way for more human-relevant, reliable preclinical drug assessment models.

MARKET RESTRAINTS

High Development and Implementation Costs to Hamper Market Expansion

The widespread adoption of organ-on-chip devices is limited by the high cost involved in their design, fabrication, and validation. The integration of advanced microfluidic sensors, systems, sensors, and human-derived cells increases the demand for specialized infrastructure and expertise. However, small biotech companies and academic labs often encounter difficulties when it comes to standardizing or affording these technologies.

Additionally, a lack of universal protocols has increased costs and slowed regulatory acceptance. These financial and technical barriers are hindering the scaling up of production and establishing consistent performance across devices, thereby impeding market growth.

MARKET OPPORTUNITIES

Expansion into Personalized Medicine Applications to Offer Lucrative Growth Opportunities

Recently, organ-on-chip technology has offered tremendous potential for creating patient-specific disease models using cells derived from individual patients. This capability has allowed researchers to test different responses in patients to the same drugs. This is paving the way for tailored treatment approaches. Moreover, the increasing demand for precision medicine is also supporting the adoption of organ-on-chip platforms, which can bridge the gap between genomics and clinical response, thereby providing functional insights about the behavioral aspects of various therapies in diverse genetic and physiological contexts. In addition, the growing adoption of induced pluripotent stem cells (iPSCs) is further enhancing this opportunity, enabling chips to represent real patient biology. As a result, researchers are developing the liver-on-a-chip model incorporating iPSC-derived hepatocytes.

• For instance, in April 2023, researchers affiliated with the Drug Discovery Institute and the Department of Computational and Systems Biology at the University of Pittsburgh, Pennsylvania, created an effective static, plate-based liver-on-a-chip model incorporating iPSC-derived hepatocytes, macrophages, and endothelial cells to evaluate drug toxicity.

ORGANS-ON-CHIPS MARKET TRENDS

Integration of AI with Multi-Organ Systems to Emerge as a Key Market Trend

The integration of organs-on-chips platforms with artificial intelligence (AI) and multi-organ “organ-on-a-chip” configurations is a significant trend in the market. AI algorithms can help enable the predictive modeling of human pharmacokinetics and disease progression, given their potential to analyze large datasets from chip experiments. More inclusive simulation of systemic drug responses has been enabled through the combination of multiple organ models, such as the gut-brain or liver-heart. This integration provides way for supporting more data-driven and faster and decision-making in the areas of toxicology, drug development, and precision healthcare research.

• For instance, in October 2025, CN Bio launched PhysioMimix Core, an all-in-one multi-organ-on-a-chip system integrated into a single microphysiological system (MPS). This platform supports validated performance across single-organ, multi-organ, and high-throughput configurations, enabling researchers to recreate complex human physiology in vitro with ease and scalability.

MARKET CHALLENGES

Regulatory Validation and Standardization Issues to Challenge Market Growth

In recent years, the lack of standardized validation guidelines is expected to pose a major challenge for market growth. Regulatory bodies, such as the FDA and EMA, have not yet fully established frameworks for integrating organ-on-chip data into drug approval processes. This discourages pharmaceutical companies from heavily investing in the technology for pivotal studies.

Moreover, the reproducibility across different platforms and laboratories remains inconsistent, complicating cross-study comparison and acceptance. This is expected to challenge the market expansion during the forecast period.

Download Free sample to learn more about this report.

Segmentation Analysis

By Offering

Increasing Outsourcing for Drug Discovery and Other Applications by Research Institutions & Pharma Companies Fueled Segmental Growth

On the basis of segmentation by offering, the market is classified into products and services. Furthermore, the product segment is sub-classified into devices and consumables & accessories.

To know how our report can help streamline your business, Speak to Analyst

The services segment dominated the global organs-on-chips market share in 2024. Several research institutions and pharmaceutical companies are opting for contract research or testing services offered by organ-on-chip providers, which deliver ready-to-use data packages for toxicity, drug efficacy, and disease modeling. This reduces setup costs, accelerates R&D, and ensures access to validated chip platforms and regulatory-grade data.

• In January 2024, CN Bio and Altis Biosystems announced a strategic partnership to develop a next-generation human gut/liver in vitro model, aiming to improve ADME (absorption, distribution, metabolism, and excretion) studies. This collaboration combines Altis’s RepliGut Planar-Jejunum gut model with CN Bio’s PhysioMimix liver-on-a-chip, creating an integrated multi-organ system that more accurately mimics oral drug administration and enhances the predictability of human drug bioavailability.

In addition, the product segment is projected to grow at a CAGR of 30.2% during the forecast period.

By Organ Model

High Significance of CGE in Nucleic Acid Analysis to Drive the Segment’s Growth

Based on the organ model, the market is segmented into liver-on-a-chip, lung-on-a-chip, intestine-on-a-chip, kidney-on-a-chip, and others.

By organ model, the liver-on-a-chip segment accounted for the largest share in 2024. The liver is the most common site of drug-induced toxicity, responsible for a significant proportion of clinical trial failures and drug withdrawals. As a result, accurate liver models are crucial for predicting human-specific drug metabolism and hepatotoxicity. This is driving the need for the development of advanced liver-on-chips, which is expected to contribute to the segment's growth. Furthermore, the segment holds 36.7% share in 2025.

In addition, the lung-on-a-chip segment is projected to grow at a CAGR of 30.0% during the forecast period.

By Application

Rapid Expansion of Drug Discovery & Development Services by Organ-on-Chip Providers Propelled Segment Growth

Based on application, the market is segmented into drug discovery & development, toxicology research, disease modeling, and others.

By application, the drug discovery & development segment accounted for the largest share in 2024. The segment's growth is attributed to the increasing focus of organs-on-chips service providers on expanding drug discovery & development services, thereby improving R&D efficiency, reducing costs, and enhancing the predictive accuracy of clinical studies. Furthermore, the segment holds 52.9% share in 2025.

• For instance, in January 2021, Emulate announced an expanded application and services roadmap for its organ-on-a-chip technology, extending its use from small molecules to advanced biologics and gene therapies, addressing complex human biology and immune responses to improve drug development.

In addition, the disease modeling segment is projected to grow at a CAGR of 30.5% during the forecast period.

By End-user

Significant Number of Pharmaceutical & Biotechnology Companies Globally to Drive the Segment Growth

Based on end-user, the market is segmented into pharmaceutical & biotechnology companies,

academic & research institutes, and others.

In 2024, the global market was dominated by pharmaceutical & biotechnology companies in terms of end-user. The growth is attributed to the significant number of pharmaceutical & biotechnology companies, utilizing organs-on-chips systems for drug discovery & development, which is increasing its demand and encouraging key players to innovate advanced systems.  Furthermore, the segment holds 55.5% share in 2025.

In addition, the academic & research institutes segment is projected to grow at a CAGR of 30.3% during the forecast period.

Organs-On-Chips Market Regional Outlook

By geography, the market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2023, valuing at USD 48.9 million, and also maintained the leading share in 2024, with USD 68.8 million. The growth is primarily driven by higher investments in research and development by pharmaceutical & biotechnology companies in the U.S., which is fueling the demand for organs-on-chips systems and attracting several key players to expand their product and service offerings. Moreover, key companies are increasingly entering into partnerships to enhance the research & development scenario in the region, which is expected to increase the utilization of organ-on-chip technology further. In 2025, the U.S. market is estimated to have reached USD 87.2 million.

• For instance, in June 2025, Hesperos, Inc. partnered with biopharmaceutical company Psilera to accelerate the preclinical development of Psilera's lead neuroplastogen compound, PSIL-006, targeting frontotemporal dementia (FTD).

Europe and Asia Pacific

Other regions, such as Europe and the Asia Pacific, are projected to grow at a substantial rate during the forecast period. Over 2025-2032, the Europe region is projected to record a growth rate of 28.8%, the second highest among all regions, and reach a valuation of USD 54.6 million by 2025. The region’s growth is mainly due to significant studies being conducted in the academic & research institutes in countries such as the U.K., and Germany. Due to such factors, countries including U.K., France, and Germany are projected to record the valuation of USD 13.7 million, USD 7.4 million, and USD 12.7 million, respectively, in the year 2025. Following Europe, the market in the Asia Pacific region is projected to reach USD 51.7 million in 2025 and emerge as the third-largest region in the global market. In the region, India and China are estimated to reach the valuation of USD 6.5 billion and USD 17.3 billion, respectively, in 2025.

Latin America and the Middle East & Africa

During the forecast period, Latin America and Middle East & Africa regions are set to depict moderate growth. In 2025,  the Latin America organs-on-chips industry is anticipated to have reached a valuation of USD 7.1 million. The growth is primarily due to the increasing partnerships between service providers and regional companies to support research studies. In the Middle East & Africa, the GCC is projected to have touched a value of USD 3.8 million by 2025.

COMPETITIVE LANDSCAPE

Key Industry Players

Strong Focus on Service Expansions and Partnerships Strengthened the Position of Prominent Players

In 2024, Emulate, MIMETAS, and InSphero collectively held the largest organs-on-chips market share. These companies are partnering with CROs, pharmaceutical companies, and research institutions, which is expected to strengthen their product and service reach globally in the upcoming years.

Other prominent companies, including CN Bio, TissUse, AIM Biotech, and others, are increasing investments to expand their offerings and focusing on the development of advanced organ-on-chip systems to capture a significant market share in the forthcoming years.

LIST OF KEY ORGANS-ON-CHIPS COMPANIES PROFILED

• Emulate (U.S.)
• MIMETAS B.V. (U.S.)
• InSphero (Switzerland)
• SynVivo, Inc. (U.S.)
• CN Bio Innovations Ltd (U.K.)
• TissUse GmbH (Germany)
• BICO (Sweden)
• AlveoliX AG (Switzerland)
• BiomimX S.r.l. (Italy)
• AIM Biotech (Singapore)

KEY INDUSTRY DEVELOPMENTS

• October 2025: CN Bio Innovations Ltd. launched PhysioMimix Core, the first all-in-one Organ-on-a-Chip (OOC) system, delivering validated performance across single-organ, multi-organ, and high-throughput configurations within a single microphysiological system.
• September 2025: The Royal Veterinary College (RVC) partnered with Emulate to develop organ-on-a-chip models, pioneering veterinary & preclinical applications and expanding access to this technology for research.
• February 2025: Xellar Biosystems entered into a sponsored research collaboration with Sanofi (via its iDEA-TECH Awards) to develop OOC models for vascular toxicity assessment.
• January 2025: PhenoVista Biosciences, a CRO, partnered with NETRI, an organ-on-chip device manufacturer, to combine PhenoVista's high-content imaging assays with NETRI’s organ-on-chip devices to offer improved functional, scalable assay services for drug development.
• September 2024: Emulate unveiled the Chip-R1 Rigid Chip, engineered with minimally drug-absorbing plastics to enhance accuracy in ADME (absorption, distribution, metabolism, and excretion) and toxicology applications.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation